Top Markets
Coin of the day
Mercury Biopharmaceutical Corporation Mercury Biopharmaceutical Corporation

Mercury Biopharmaceutical Corporation

6932
株式のランク #23452
Founded in 2019 and headquartered in New Taipei City, Taiwan, Mercury... Founded in 2019 and headquartered in New Taipei City, Taiwan, Mercury Biopharmaceutical Corporation is dedicated to creating innovative pharmaceutical solutions for medical conditions currently lacking adequate treatment options. A cornerstone of their strategy is the proprietary StackDose platform, an advanced drug development system designed to formulate novel medication delivery methods. This platform facilitates precisely timed drug release, targeted absorption at specific locations within the body, and flexible dosage modifications. The primary objective of StackDose is to significantly boost the bioavailability of active pharmaceutical ingredients, leading to a reduction in required drug dosages and fewer adverse effects. Their development pipeline currently addresses a variety of ailments, such as erectile dysfunction, pulmonary hypertension, sleep disturbances, benign prostatic hyperplasia, angina, migraines, hypertension, and pain management.
株価
$0.17616661
最終同期: 2026-08-21
時価総額
$73.48M
変化(1日)
0.18%
変化(1年)
-37.76%
TW
取引 Mercury Biopharmaceutical Corporation (6932)

カテゴリー

Mercury Biopharmaceutical Corporation(6932)の利益
2026 時点の利益 TTM: 0
Mercury Biopharmaceutical Corporation の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Mercury Biopharmaceutical Corporation の利益の推移(2026 〜 2026)
各年末の利益
利益 変化
提供された日付のデータは十分ではありません。